hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06331910, orgStudyIdInfo id: TITNCUES, briefTitle: Efficacy and Safety of Topical Insulin for Neurotrophic Corneal Ulcers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: To evaluate Safety and efficacy of topical insulin in treatment of neurotrophic corneal ulcers, conditionsModule conditions: Neurotrophic Keratopathy, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ESTIMATED, armsInterventionsModule interventions name: insulin eye drops, outcomesModule primaryOutcomes measure: Decrease in ulcer size and the increase in visual acuity ., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06331897, orgStudyIdInfo id: Bronchial asthma, briefTitle: Bronchial Asthma & Its Exacerbation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-01-01, primaryCompletionDateStruct date: 2026-01-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Our goals is to assess :1¬_ the role of spirometer in case of asthma exacerbation 2_hematological parameters (N/L ratio \&amp; platelet indices \&amp;CRP )in asthma exacerbation for diagnosing and classifying asthma severity and its exacerbation, conditionsModule conditions: Bronchial Asthma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, outcomesModule primaryOutcomes measure: Assessment of Broncial asthma & its exacerbation : the utility of laboratory investigation, chest imaging, pulmonary function tests, eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06331884, orgStudyIdInfo id: PCZ_Phase1, briefTitle: Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-07, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: 4TEEN4 Pharmaceuticals GmbH, class: INDUSTRY, descriptionModule briefSummary: Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of several cardiovascular mediators. During cardiogenic shock, upregulation of the vasoconstrictive molecule angiotensin II is a physiologic and potentially life-saving response aimed at maintaining adequate tissue perfusion. As circulating (c)DPP3 is able to effectively cleave angiotensin II, it may represent a novel factor contributing to hemodynamic instability during cardiogenic shock.Recently, a cDPP3-antagonizing antibody called AK1967 (commonly referred to as Procizumab) has been developed. In animal models of cardiogenic- and septic shock, inhibition of cDPP3 by AK1967 resulted in improved cardiac function and survival. Furthermore, AK1967 has shown an excellent safety record in different preclinical studies. In the current study the safety, tolerability and pharmacokinetics/-dynamics of AK1967 will be investigated in healthy male subjects., conditionsModule conditions: Safety and Tolerability, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: AK1967 (Procizumab), interventions name: Placebo, outcomesModule primaryOutcomes measure: Reported number of adverse events from baseline (start of Procizumab administration) up until the last follow-up visit after Procizumab administration, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Radboud University Medical Center, status: RECRUITING, city: Nijmegen, state: Gelderland, zip: 6525, country: Netherlands, contacts name: Peter Pickkers, MD, PhD, role: CONTACT, geoPoint lat: 51.8425, lon: 5.85278, hasResults: False
protocolSection identificationModule nctId: NCT06331871, orgStudyIdInfo id: 2004202111621, briefTitle: Effectiveness of US-PENS for Patients With Post-surgical Shoulder Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2025-10-30, completionDateStruct date: 2025-10-30, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Universidad Rey Juan Carlos, class: OTHER, descriptionModule briefSummary: The aim of this clinical trial was to demonstrate the effectiveness of the application of ultrasound-guided percutaneous nerve stimulation (US-PENS) directed at the axillary nerve and the suprascapular nerve, in patients with post-surgical shoulder pain.This is a randomized, longitudinal, prospective and quasi-experimental clinical trial in which a total of 70 patients divided into two groups; physiotherapy protocol group (n=35) and experimental group to which the same protocol was practiced and a US-PENS session was added (n=35).The intervention and follow-up period of the participants took place over 12 weeks., conditionsModule conditions: Ultrasound-Guided Percutaneous Electrical Nerve Stimulation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 70 patients with shoulder pain undergoing arthroscopic surgery were recruited. They were divided into two groups at random; physiotherapy protocol group (n=35) and experimental group to which the same protocol was practiced and two sessions of ultrasound-guided percutaneous nerve stimulation (US-PENS) were added (n=35)., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound Guied Percutaneus Electrical Nerve Stimulation (US-PENS) and Manual physiotherapy protocol based on available evidence., interventions name: Manual physiotherapy protocol based on available evidence., outcomesModule primaryOutcomes measure: The Numeric Pain Rating Scale (NPRS), primaryOutcomes measure: Disabilities of the Arm, Shoulder and Hand (DASH), primaryOutcomes measure: The Shoulder Pain and Disability Index (SPADI), primaryOutcomes measure: GONIOMETRY, primaryOutcomes measure: DINAMOMETRY, primaryOutcomes measure: PAIN THRESHOLD ON PRESSURE, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinica Cemtro, status: RECRUITING, city: Madrid, zip: 28049, country: Spain, contacts name: MARIO J ABRIL SERVÁN, role: CONTACT, phone: +34636707810, email: MASERVAN@HOTMAIL.COM, contacts name: FERNANDO GARCÍA SANZ, role: CONTACT, phone: +34917355757, email: fisioterapiaclub@clinicacemtro.com, contacts name: MARIO J ABRIL SERVÁN, role: PRINCIPAL_INVESTIGATOR, contacts name: ADRIÁN CASES, role: SUB_INVESTIGATOR, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06331858, orgStudyIdInfo id: KutahyaHSU-DRGOKPINARDROMER-43, briefTitle: The Effect of Adding Instrumented Hip Concentric Abductor Strengthening Exercise in Knee Osteoarthritis, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-20, primaryCompletionDateStruct date: 2024-03-29, completionDateStruct date: 2024-03-29, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Kutahya Health Sciences University, class: OTHER, descriptionModule briefSummary: The aim of this study was to investigate the effectiveness of adding hip device-assisted concentric abductor strengthening (HDACAS) program to knee device-assisted concentric flexor-extensor strengthening (KDACFES) program on pain, function, physical performance, quality of life and gait parameters in patients with knee osteoarthritis (OA)., conditionsModule conditions: Knee Osteoarthritis, conditions: Pain, conditions: Physical Disability, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 1. STUDY GROUP2. CONTROL GROUP, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Before and after the treatment, all patients were evaluated by a blind evaluator in terms of physical examination, pain and functionality, physical performance, quality of life and gait parameters., whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: hip device-assisted concentric abductor strengthening (HDACAS), interventions name: knee device-assisted concentric flexor-extensor strengthening (KDACFES), outcomesModule primaryOutcomes measure: Western Ontario and McMaster Universities (WOMAC), primaryOutcomes measure: The Lequesne Algofunctional index, primaryOutcomes measure: TIME UP AND GO TEST, primaryOutcomes measure: 30 SECOND CHAIR TEST, primaryOutcomes measure: 40 METER SELF PACED WALK TEST, primaryOutcomes measure: SIX MINUTES WALK TEST, primaryOutcomes measure: STAIR CLIMB TEST, secondaryOutcomes measure: Visual Analog Scale (VAS), secondaryOutcomes measure: Mini Osteoarthritis Knee and Hip Quality of Life Scale, eligibilityModule sex: ALL, minimumAge: 45 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kutahya Health Sciences University, status: RECRUITING, city: Kutahya, zip: 43100, country: Turkey, contacts name: Hasan Huseyin Gokpinar, Ass. Prof., role: CONTACT, phone: +905052842222, email: hasanhuseyin.gokpinar@ksbu.edu.tr, contacts name: Ömer Özyümlü, role: CONTACT, phone: +905442024671, email: omer.ozyumlu@gmail.com, geoPoint lat: 39.42417, lon: 29.98333, locations facility: Kutahya Health Sciences University, status: RECRUITING, city: Kutahya, zip: 43100, country: Turkey, contacts name: Hasan Huseyin Gokpinar, Ass. Prof., role: CONTACT, phone: +905052842222, email: hasanhuseyin.gokpinar@ksbu.edu.tr, geoPoint lat: 39.42417, lon: 29.98333, hasResults: False
protocolSection identificationModule nctId: NCT06331845, orgStudyIdInfo id: NPC012, briefTitle: Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2028-05-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Fujian Cancer Hospital, class: OTHER_GOV, descriptionModule briefSummary: This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic chemotherapy (SC)., conditionsModule conditions: Metastatic Nasopharyngeal Carcinoma, conditions: Intermittent Systematic Chemotherapy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 39, type: ESTIMATED, armsInterventionsModule interventions name: Gemcitabine, interventions name: Cisplatin, interventions name: Paclitaxel protein-bound, interventions name: Capecitabine, interventions name: Tislelizumab, outcomesModule primaryOutcomes measure: progression-free survival, secondaryOutcomes measure: progression-free survival 2, secondaryOutcomes measure: overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06331832, orgStudyIdInfo id: 2323-EAP, secondaryIdInfos id: 2021-002339-44, type: EUDRACT_NUMBER, briefTitle: Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL, statusModule overallStatus: NO_LONGER_AVAILABLE, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: IGM Biosciences, Inc., class: INDUSTRY, descriptionModule briefSummary: Expanded Access of Imvotamab (IGM-2323) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial., conditionsModule conditions: Relapsed/Refractory Non-Hodgkin Lymphomas, designModule studyType: EXPANDED_ACCESS, armsInterventionsModule interventions name: IGM2323, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sir Charles Gairdner Hospital, city: Nedlands, state: Western Australia, country: Australia, geoPoint lat: -31.98184, lon: 115.8073, locations facility: Samsung Medical Center, city: Seoul, state: Gangnam-gu, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, locations facility: START-Madrid Centro Integral Oncologico Clara Campal, city: Madrid, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06331806, orgStudyIdInfo id: IEO 398, briefTitle: Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-02-22, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment, conditionsModule conditions: Cardiomyopathy Due to Drug, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Evaluation of myocardial fibrosis, outcomesModule primaryOutcomes measure: Evaluation of blood levels of Suppression Of Tumorigenicity 2 (ST2), primaryOutcomes measure: Evaluation of blood levels of Galectin-3 (Gal-3), primaryOutcomes measure: Evaluation of Enhanced Liver Fibrosis score (ELF), primaryOutcomes measure: Evaluation of CMR imaging marker of fibrosis, secondaryOutcomes measure: Evaluation of response to heart failure treatment, secondaryOutcomes measure: Evaluation of levels of Troponin I (TnI) and B-type Natriuretic Peptide (BNP), secondaryOutcomes measure: Evaluation of levels of cytochrome C, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Daniela Cardinale, MD, role: CONTACT, email: daniela.cardinale@ieo.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06331793, orgStudyIdInfo id: IEO 1849, briefTitle: Pulsed Electromagnetic Fields for Analgesia Post Mastectomy, acronym: Algocare, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-09, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: Study aim is to test AlgoCare, a device that uses the technology PEMF (Pulsed ElectroMagnetic Fields) for the treatment of postoperative pain in oncological breast surgery, in order to demonstrate that the use of Algocare in the postoperative period allows for a reduction in pain intensity in terms of Numerical Rating Scale (NRS) score and use of analgesic drugs., conditionsModule conditions: Female Breast Cancer, conditions: Post Operative Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomization 1:1, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Double blind, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: Active AlgoCare, interventions name: Non-active AlgoCare, outcomesModule primaryOutcomes measure: Pain intensity, secondaryOutcomes measure: Need for analgesic drugs, secondaryOutcomes measure: Patient reported pain characteristics, secondaryOutcomes measure: Number of participants with other symptoms, secondaryOutcomes measure: Need for other drugs, secondaryOutcomes measure: Wound healing timing, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, zip: 20141, country: Italy, contacts name: Daniele Sances, MD, role: CONTACT, phone: +390257489618, email: daniele.sances@ieo.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06331780, orgStudyIdInfo id: WS10370, secondaryIdInfos id: 2023-A02153-42, type: OTHER, domain: ANSM (France), briefTitle: Refractive Status and Accommodation Response Under Different Experimental Conditions., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-22, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Essilor International, class: INDUSTRY, descriptionModule briefSummary: Eye Care Professionals (ECPs) massively use auto-refractors during the patient journey to measure the objective refractive error: starting point of the subjective eye refraction. These devices provide objective information about the refractive and accommodative state of the eye, useful for the ECP to perform a complete eyesight test. Auto-refractor data for the distance vision are repeatable and accurate but near vision information are not enough reliable to build an accurate near vision routine exam. Previous internal studies, with auto refractors currently on the market, have shown that, during accommodation measurements, a large proportion of participants had a lower accommodative response than expected., conditionsModule conditions: Accommodation Disorder, conditions: Accommodative Fatigue, conditions: Accommodative Inertia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 55, type: ESTIMATED, armsInterventionsModule interventions name: Visual acuity, interventions name: Objective refraction, interventions name: Objective monocular accommodation amplitude measurement, interventions name: Subjective monocular accommodation amplitude measurement with the "Push-Up" method, interventions name: Subjective monocular accommodation facility measurement with the "Rock" method:, interventions name: CISS Questionnaire, interventions name: Difficulty assessment questionnaire, interventions name: Subjective evaluation questionnaire, outcomesModule primaryOutcomes measure: Accommodative response measured with closed-field aberrometer with different target displacement methods, primaryOutcomes measure: Accommodative response measured with closed-field aberrometer with different displayed targets, primaryOutcomes measure: Objective refraction measured with closed-field aberrometer and two camera exposure times, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Essilor International - Ci&T 2, status: RECRUITING, city: Créteil, zip: 94000, country: France, contacts name: Jérôme Gillet, role: CONTACT, phone: +33 (0)1 49 80 63 40, email: gilletj@essilor.fr, geoPoint lat: 48.78333, lon: 2.46667, hasResults: False
protocolSection identificationModule nctId: NCT06331767, orgStudyIdInfo id: 2024P000654, briefTitle: Development of a Multilevel HIV Prevention Intervention for the Emergency Department, acronym: mSYNC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2029-04, completionDateStruct date: 2029-04, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Brigham and Women's Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to pilot test a psychosocial-behavioral mobile health (mHealth) human immunodeficiency virus (HIV) prevention intervention in people who use drugs presenting to the emergency department (ED). The main question the study aims to answer is: is the intervention acceptable and appropriate? Participants will use the mHealth app while waiting in the ED and also at home for 90 days. Participants will be asked to complete surveys at baseline, before leaving the ED, and at 30-, 60-, and 90-day follow up visits., conditionsModule conditions: HIV, conditions: Drug Use, conditions: Mental Health, conditions: Psychological Distress, conditions: Social Marginalization, conditions: Problems With Access to Health Care, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: mSYNC, outcomesModule primaryOutcomes measure: Acceptability, primaryOutcomes measure: Acceptability, primaryOutcomes measure: Acceptability, primaryOutcomes measure: Appropriateness, primaryOutcomes measure: Appropriateness, primaryOutcomes measure: Appropriateness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False